This review examines the role of platelets in ischemic stroke, platelet activation mechanisms,
aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible …

Antiplatelet agents are the medications of choice for preventing non-cardioembolic strokes.
The diverse pathways involved in platelet function suggest the possibility of synergistic …

Aspirin (acetylsalicylic acid) is the most widely studied and prescribed antiplatelet drug for
patients at high risk of vascular disease. It affects a single pathway in the platelet activation …

Antiplatelets are the pivotal drugs in preventing recurrent stroke or other major vascular
events in patients who have undergone TIA or stroke. Aspirin is the most widely used …

Opinion statement Though antiplatelet agents are the mainstay of antithrombotic therapy for
secondary prevention of noncardioembolic cerebral ischemic events, the efficacy of …

Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic
stroke. The recent results of the CAPRIE, CURE, and CREDO studies formed the rationale …

Drugs that prevent platelets from sticking together—ie, aspirin, dipyridamole, and
clopidogrel—are an important part of therapy to prevent recurrence of ischemic stroke of …

Despite recent advances in the acute treatment of stroke, prevention and risk factor
modification remain the mainstays of management for patients with ischemic stroke and …

Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke
of between 5% and 20% per year. In patients with TIA or ischemic stroke of non-cardiac …

Antiplatelet therapy has proven efficacy in the secondary prevention of recurrent non-
cardioembolic ischaemic stroke. Recent evidence suggests clopidogrel is as effective as …